News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Novartis AG Withdraws Joicela Marketing Application in Europe
April 19, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Novartis AG (NOVN) withdrew its application to market the Joicela pain pill in the European Union because the Swiss company wasn’t able to provide information to regulators in the time allowed.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Novartis
MORE ON THIS TOPIC
FDA
US government launches AI-driven programs to overhaul clinical trials
October 1, 2026
·
4 min read
·
Gabrielle Masson
Insights
The race for access: How the FAIR Act could reclaim U.S. biotech leadership
October 1, 2026
·
1 min read
·
Jennifer C. Smith-Parker
FDA
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
September 30, 2026
·
3 min read
·
Heather McKenzie
FDA
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
September 30, 2026
·
1 min read
·
Jef Akst
